NEW YORK, Oct. 29, 2018 /PRNewswire/ -- Spherix
Incorporated (Nasdaq: SPEX) today announced that it has added Dr.
Rana Quraishi to the Company's
Advisory Board to assist the Company in evaluating potential
opportunities in the biopharmaceutical area.
Dr. Rana Quraishi is the Director
of New Ventures, at UM Ventures University of
Maryland, Baltimore. UM Ventures is a joint initiative
bringing the University of Maryland,
Baltimore and University of Maryland,
College Park together to commercialize discoveries and
create economic impact by engaging partners in industry and social
ventures. Dr. Quraishi has a Ph.D. in Molecular Biology and
Biochemistry from Columbia University
where she was also an undergraduate and an M.S. from Harvard University.
Dr. Quraishi has spent much of her career working in life
science directed finance, investment and consulting
organizations.
At the TCG Group, a premiere private equity firm, she focused on
business development opportunities for its life science companies.
Prior to this, she was a Principal at Conning Capital
Partners/SwissRe an early stage private equity fund providing
growth capital for entrepreneurial companies where she served on
Boards of several portfolio companies.
Dr. Quraishi also served as CFO/Senior Advisor for Helicon
Therapeutics, a start-up with assets contributed by Cold Spring Harbor and OSI Pharmaceuticals.
She developed the company's business plan and made investor
presentations leading to initial funding. Helicon was subsequently
acquired.
Earlier in her career Dr. Quraishi worked for Standard and
Poor's, GE Capital where she was Commercial Quality Leader for GE
Capital and prior to that headed the Business Development Group at
its FGIC subsidiary, J.E. Seagram and American Express where she
led treasury and acquisitions and divestitures groups.
She has served on several for-profit and not for-profit boards
and has also authored the widely read "Market Demand Study for
Commercial Biotechnology, Biomedical, and Bioinformatics Facilities
in New York City" for the New York
City Partnership and Investment Fund.
Dr. Quraishi stated, "I'm committed to moving pioneering
technologies toward commercialization and delighted to join the
Spherix Advisory Board to advance that effort."
Anthony Hayes, the Chief
Executive Officer of Spherix stated, "We continue to make strategic
investments in both biotechnology and human capital. Dr. Quraishi
is another checkmark to assist us in our transformation into a
biotech company. We are confident her experience and industry
knowledge will assist Spherix through these exciting times. All of
the pieces are coming together with the recently announced proposed
merger with CBM and its ground breaking drug research.
About Spherix Incorporated
Spherix Incorporated was launched in 1967 as a scientific
research company. Spherix is committed to advancing innovation by
participation in the development of new technology. Spherix draws
on portfolios of pioneering technology to support product
innovation.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. We are a small
company with limited financial resources and our scientific
background and abilities to implement a commercialization strategy
is subject to ever-changing market conditions and rapidly-advancing
technologies over which we have no control. While we believe that
these forward-looking statements are reasonable, market conditions
and competition in the marketplace is ever-changing and we have no
control over these influences. As a result, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties,
including without limitation those set forth in the Company's
filings with the Securities and Exchange Commission (the "SEC")
including, but not limited to, the Risk Factors relating to the
Company's patent business and other aspects of the Company's
business contained therein. Thus, actual results could be
materially different. The Company expressly disclaims any
obligation to update or alter statements whether as a result of new
information, future events or otherwise, except as required by
law.
Contact:
|
|
Investor
Relations:
|
Hayden IR
|
Brett Maas, Managing
Partner
|
Phone: (646)
536-7331
|
Email:
brett@haydenir.com
|
www.haydenir.com
|
|
|
Spherix:
|
Phone:
212-745-1373
|
Email:
investorrelations@spherix.com
|
www.spherix.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/spherix-announces-the-addition-of-dr-rana-quraishi-to-companys-advisory-board-300739216.html
SOURCE Spherix Incorporated